Are AstraZeneca plc & GlaxoSmithKline plc A Sound Investment Right Now?

AstraZeneca plc (LON:AZN) and GlaxoSmithKline plc (LON:GSK) could outperform companies operating in more troubled sectors, and for different reasons, argues this Fool.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

“You don’t want to be a stock broker these days my friend”, a senior cash equity trader told me this week. Why so? 

The FTSE 100 has been under pressure as investors contemplate what the consequences of a Yes vote in Scotland might be on September 18. “Opportunity or threat?” is the recurring question. On top of that, China came again under the spotlight on Monday as it struggles to grow its economy. Moreover, traders around the globe need direction from the Federal Reserve later this week. 

UK Pharma Stocks

The valuations of most pharma stocks are out of whack with reality, true. But the shockwaves are being felt in other sectors — look at the shares of ARM, Associated British Foods and ASOS, to name a few. That, is turn, should boost the appeal of the pharmaceutical space. Easy, right?

astrazeneca2

You may be safe if you invest in the pharma space now with a three-month investment horizon, although it must be noted that the shares of AstraZeneca (LSE: AZN) and Hikma Pharmaceuticals (LSE: HIK) — as well as those of a medical devices maker such as Smith & Nephew (LSE: SN)are seriously expensive. The outlier is GlaxoSmithKline (LSE: GSK), in my view.

Looking For A Truly Defensive Play? 

AstraZeneca stock has been trading above fair value for some time. It has risen by more than 10% in the last month alone, and its main attraction is that Astra is still considered a takeover target for Pfizer. The shares have recorded a performance of +27% in 2014. Astra’s trading multiples suggest plenty of possible downside, but more volatile market conditions may provide a support to the stock. Astra’s yield is truly appealing — other metrics less so. 

Glaxo, for its part, is between a rock and a hard place. Glaxo stock has performed relatively well in the last few weeks, but it appears evident that investors aren’t convinced about the company’s prospects. The bribery scandal in China is a big unsolved problem, too. Nevertheless, I believe Glaxo is a sound bet for value investors. Very possibly, this is the best play in the sector.

Elsewhere, Hikma has recently come under the spotlight because it may attract interest from third parties. Its stock, however, looks fully valued at this level. It has risen by 37% year to date, but has lost 6% of value in the last four weeks of trading. I don’t think Hikma is a great opportunity right now. 

On the face of it, the same applies to Smith & Nephew, whose shareholders have been long waiting for an offer to materialise. They have enjoyed significant upside from takeover speculations, which are clearly priced into the shares. S&N is a solid business operating in a sector where consolidation is on the cards. Its shares trade at 12.7x and 11x adjusted operating cash flow for 2014 and 2015, respectively. These trading multiples are not incredibly attractive, but is S&N a buy in this environment?

“You know, other options are thin on the ground…” my source reminded me. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. The Motley Fool UK owns shares of Smith & Nephew. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »

Investing Articles

What might the 5-year price chart tell us about BT shares?

Christopher Ruane considers what clues the long-term performance of BT shares might offer him about business performance and whether to…

Read more »